Amarin Corporation plc (NASDAQ: AMRN) negotiated 4,413,732 shares against it an average volume of 5,295,325 shares. The stock concluded the recent trade at $19.39 with upbeat trend move of +3.58%. The company has total market value of 6.412 billion. The company has got a 52-week exceptional price of $23.33 and reached a 52-week lowest of the share price at $2.35 . The daily trading range was observed between a day’s low price of $18.73 to a day’s high price of $19.43.
Amarin Corporation plc (NASDAQ: AMRN), recently reported financial results for the quarter ended March 31, 2019.
Net product revenue, for three months ended March 31, 2019 and 2018 was about $72.7M and $43.8M.
In addition, Amarin recognized licensing revenue of about $0.5M and $0.1M for the quarters ended March 31, 2019 and 2018, respectively, under contracts for the commercialization of Vascepa outside the U.S.
Cost of goods sold for the three months ended March 31, 2019 and 2018 was $17.1M and $10.6M, respectively.
Selling, general and administrative (SG&A) expenses in the three months ended March 31, 2019 and 2018 were $71.6M and $43.4M, respectively. This 65% increase in SG&A expenses supported a 67% increase in net total revenue and is intended to help support future revenue growth consistent with the company’s before expressed guidance that 2019 revenue levels will grow at least 50% over 2018 levels to about $350M in 2019.
Under U.S. GAAP, Amarin stated a net loss of $24.4M in the first quarter of 2019, or basic and diluted loss per share of $0.07. This net loss included $6.9M in non-cash stock-based compensation expense. Amarin stated a net loss of $24.1M in the first quarter of 2018, or basic and diluted loss per share of $0.08. This net loss included $3.8M in non-cash stock-based compensation expense.
Not Including non-cash gains or losses for stock-based compensation, non-GAAP adjusted net loss was $17.5M for the first quarter of 2019, or non-GAAP adjusted basic and diluted loss per share of $0.05, contrast to non-GAAP adjusted net loss of $20.3M for the first quarter of 2018, or non-GAAP adjusted basic and diluted loss per share of $0.07.
As of March 31, 2019, Amarin stated cash and cash equivalents of $211.1M, $79.5M in net accounts receivable ($104.0M in gross accounts receivable before allowances and reserves) and $57.9M in inventory. In connection with the recently adopted lease standard, ASC 842, the company recorded an operating lease right-of-use asset and corresponding operating lease liability of about $9.0M.
As of March 31, 2019, Amarin had about 330.6M American Depository Shares (ADSs) and ordinary shares outstanding, 28.9M ordinary share equivalents of Series a Convertible Preferred Shares outstanding and about 16.8M equivalent shares underlying stock options at a weighted-average exercise price of $5.51, as well as 9.3M equivalent shares underlying restricted or deferred stock units.